Published in Telemedicine Business Week, September 29th, 2004
The company intends to redirect some of the approximately $10 million it projected to spend on the Hynic-Annexin V program in fiscal 2005 to other product development opportunities, with particular focus on its intensity modulated radiation therapy (IMRT) and image guided radiation therapy (IGRT) products.
"Despite the fact that our Hynic-Annexin V program continues to yield compelling clinical data, it has become clear to me...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Telemedicine Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.